S&P/ASX All Ordinaries Index (ASX: XAO) shares are 0.37% higher at 9,137.7 points on Tuesday.
The ASX All Ords has risen 8% over the year to date, but many stocks have experienced much larger moves in opposite directions.
On The Bull, three experts explain why these three ASX All Ords shares are worth holding despite major price shifts in 2025.
Image source: Getty Images
3 ASX shares worth holding despite big price shifts
HUB24 Ltd (ASX: HUB)
The Hub24 share price has soared 55% in the year to date.
Today, Hub24 shares are $106.93, up 1.4%.
Andrew Wielandt from DP Wealth Advisory has a hold rating on this ASX All Ords financial share.
The analyst summarised the investment and superannuation provider's recent results:
This investment and superannuation platform provider is a strong performer.
It generated total revenue of $406.6 million in fiscal year 2025, up 24 per cent on the prior corresponding period.
Statutory net profit after tax of $79.5 million was up 68 per cent.
Total funds under administration reached $136.4 billion, an increase of 30 per cent.
The number of active advisors using the HUB24 platform increased to 5097 in fiscal year 2025, up 13 per cent.
While the ASX All Ords financial share has risen strongly this year, the analyst expects it to sustain investors' favour.
Wielandt says:
The shares should be supported by a sound return on equity and profit margin.
However, a strong share price performance and demanding price/earnings ratio leaves HUB as a hold at this point.
Aussie Broadband Ltd (ASX: ABB)
The Aussie Broadband share price has also leapt 55% in the year to date.
Aussie Broadband shares are steady at $5.50 on Tuesday.
Wielandt also has a hold rating on this ASX All Ords communications share.
He explains:
Revenue from ordinary activities of $1.187 billion in fiscal year 2025 was up 18.7 per cent on the prior corresponding period.
Net profit after tax of $32.8 million was up 24.5 per cent. Broadband connections of 788,000 across the group were up on the previous year.
Aussie was rewarded by investors after announcing the sale of its discount brand Buddy Telco to Tangerine Telecom for about $8 million.
The stock was recently trading around consensus, so we retain a hold recommendation.
Telix Pharmaceuticals Ltd (ASX: TLX)
The Telix Pharmaceuticals share price has gone in the opposite direction this year.
Telix Pharmaceuticals shares are down 28% in the year to date.
Today, Telix Pharmaceuticals shares are $16.85, up 12%.
This follows news that Telix has been given special payment status for its next-generation PSMA-PET1 imaging agent for prostate cancer.
Mark Gardner from MPC Markets has a hold rating on this ASX All Ords healthcare share.
He says:
Telix is a commercial stage biopharmaceutical company.
On September 9, TLX announced it had reached an agreement with the US Food and Drug Administration on a re-submission pathway for its new drug application Pixclara, an investigational agent for the imaging of glioma, which is a rare and life-threatening brain cancer.
In our view, investors should consider waiting for regulatory clarity before reassessing their positions in TLX.
